Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus.

ABSTRACT: Background/Objectives: The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children and adults. With nearly everyone infected by the age of five, there is an opportunity to develop booster vaccines that enhance B-cell immunity, promoting potent and broadly neutralizing antibodies. One potential approach involves using anti-idiotypic antibodies (anti-IDs) to mimic specific antigenic sites and enhance preexisting immunity in an epitope-specific manner. RB1, a monoclonal antibody (mAb) that binds to site IV of the RSV fusion (RSV F) protein, is a potent and broadly neutralizing against RSV A and B viruses. It is the precursor for MK1654 (clesrovimab), which successfully completed a Phase III clinical trial. Methods: In this study, we i

SUBMITTER: Mukhopadhyay S 

PROVIDER: S-EPMC11768756 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature